MIRM vs NAMS Stock Comparison

MIRM currently leads NAMS in this stock comparison, with AIQ scores of 53 vs 41. The clearest difference is momentum, while NAMS has the stronger quality profile.

Market data as of Nov 15, 2026 market close· AIQ score gap 12 points
MIRM
Healthcare
vs
NAMS
Healthcare
MIRM
Mirum Pharmaceuticals, Inc.
Leads
Price
$93.99
Day move
+0.71%
AIQ Score
53/100
Best edge
Momentum
Sector
Healthcare
NAMS
NewAmsterdam Pharma Company N.V.
Price
$20.14
Day move
+0.85%
AIQ Score
41/100
Best edge
Quality
Sector
Healthcare

What is the main difference between MIRM and NAMS?

MIRM leads the current stock comparison as Mirum Pharmaceuticals, Inc., with the clearest separation coming from momentum and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Mirum Pharmaceuticals, Inc. vs NewAmsterdam Pharma Company N.V.

Data as of Nov 15, 2026· market close· Healthcare· Coverage 64/66 fields· High confidence
AIQ VerdictCompetitiveAIQ Comparison Conviction 6/10

MIRM leads

MIRM leads by 12 AIQ points, primarily on Momentum and Value. Wall Street currently favors NAMS on target upside.

Competitive: 3 of 6 evidence groups support MIRM, and its current signal state is conflicted.

Evidence agreement: 3 of 6Comparison trend: Stable
MIRM

Mirum Pharmaceuticals, Inc.

Leads
AIQ Score
53/100
AIQ Edge Score
5/10
NAMS

NewAmsterdam Pharma Company N.V.

AIQ Score
41/100
AIQ Edge Score
2/10

The Algovestiq AIQ Score currently favors MIRM over NAMS, 53 versus 41 as of Nov 15, 2026. MIRM's advantage is driven primarily by stronger momentum and value, while NAMS holds the stronger quality profile. MIRM also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors NAMS. 3 of 6 covered evidence groups favor MIRM today, and the comparison is rated Competitive on stability: only 3 of 6 covered evidence groups agree. MIRM lead: Stable — the AIQ differential has held near 12 points over 30 sessions.

Compare Mirum Pharmaceuticals, Inc. and NewAmsterdam Pharma Company N.V. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Price return from daily closes; distributions are not included.

MIRM
+381.0%
NAMS
+94.6%

Price return comparison

Growth of $10,000, price only

MIRM $48,101 · NAMS $19,459

Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.

Compare MIRM and NAMS against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

MIRM advantage
0
NAMS advantage
  • Momentum54 vs 22
    MIRM +32
  • Value57 vs 42
    MIRM +15
  • Quality52 vs 58
    NAMS +6
  • Risk Resilience51 vs 48
    Even

3 of 6 evidence groups favor MIRM. MIRM’s edge is concentrated in momentum and value; NAMS keeps a meaningful quality edge.

What changed since the last close

Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.

MIRM+1 AIQ

Largest factor move: Momentum +2

No signal started or stopped since the prior session; its 4 active signals are unchanged.

NAMS0 AIQ

Largest factor move: Value +2, not enough on its own to move the overall score.

No signal started or stopped since the prior session; its 6 active signals are unchanged.

MIRM's lead widened by 1 AIQ point in the latest session.

Deeper signal detail for each name lives on its own signals page — MIRM and NAMS both carry a full feed there.

The central trade-off

MIRM (Mirum Pharmaceuticals, Inc.): the stronger current systematic profile, led by momentum and value.

NAMS (NewAmsterdam Pharma Company N.V.): the counter-case, on quality, fundamentals, analyst expectations — but at materially higher volatility, 69.8% against 50.6%.

The AIQ Score and Wall Street therefore point in different directions on this pair.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

MIRM

MIRM on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

NAMS

NAMS on combined revenue and EPS growth.

Value

MIRM

MIRM on the peer-relative Value factor, by 15 points.

Momentum

MIRM

MIRM on the Momentum factor, by 32 points.

Lower downside

MIRM

MIRM carries the lower 1-month annualized volatility.

Analyst upside

NAMS

NAMS on implied upside to the consensus price target.

AIQ vs Wall Street

The model and the Street disagree here: AIQ favors MIRM, analyst targets favor NAMS. That disagreement is the most useful thing on this page.

MeasureMIRMNAMSNote
Implied upside to target+66.9%+202.9%NAMS has more room
Target dispersion+45.9%0%Lower is tighter analyst agreement
ConsensusBuyBuyContext, not a primary driver
Analysts covering1416Higher coverage generally improves confidence

The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

3 of 6 covered evidence groups favor MIRM. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreMIRM53 vs 41
FundamentalsNAMSon balancerevenue growth 5.4% vs 4.2%; EPS growth 41.5% vs 73.1%; TTM ROE 75.2% vs -2.8%; gross margin 81.7% vs 97.8%; operating margin -25.3% vs -9% — NAMS takes 3 of 5 decided legs, not all of them
ValuationMIRMValue 57 vs 42
TechnicalsMIRMPrice vs 50-day 5.9% vs -6.4%; vs 200-day -4.5% vs -30.9%
Risk ResilienceEvenRisk Resilience 51 vs 48
Analyst expectationsNAMSTarget upside 66.9% vs 202.9%

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of MIRM and NAMS and are excluded from the count.

AIQ Decision Stability

Competitive

The two are close enough that your objective, not the score, should decide.

  • The AIQ gap is wide at 12 points. (supports the conclusion holding)
  • Only 3 of 6 covered evidence groups agree. (argues the conclusion is provisional)
  • The lead has been steady session to session. (supports the conclusion holding)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on MIRM.

How the comparison changed

120 daily snapshots · May 27 – Nov 13

MIRM lead: Stable — the AIQ differential has held near 12 points over 30 sessions.

May 27MIRM leads above the line · NAMS leads belowNov 13
Today
MIRM +12
53 vs 41
7 sessions ago
MIRM +11
50 vs 39
30 sessions ago
MIRM +13
47 vs 34
90 sessions ago
MIRM +13
53 vs 40

The lead has not changed hands in this window.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

MIRMConflicted

1 bullish / 2 bearish / 1 neutral, conflicted

Only MIRM

  • Low Volume Rally Warning — bearish, volume, short horizon (0.54x)
  • TRIX Bullish Signal — bullish, momentum, short horizon
NAMSConflicted

1 bullish / 3 bearish / 2 neutral, conflicted

Only NAMS

  • ADX Trend Weakening — neutral, trend, medium horizon
  • Beta Spike Warning — bearish, risk_regime, long horizon
  • Downtrend Structure Active — bearish, trend, long horizon
  • MACD Histogram Expanding Bullish — bullish, momentum, short horizon

Both carry 2 more signals that do not separate them: Death Cross Active, ATR Expansion - Breakout Mode.

MIRM leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

MIRMConfirmed strength

Price and the AIQ Score both moved up over the latest session (price +0.71%, AIQ +1 points).

NAMSNo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +0.85%, AIQ 0 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1NAMS closes the Momentum gap — currently 32 points behind, the largest single contributor to MIRM's edge.
  2. 2NAMS's Death Cross Active resolves — a bearish trend rule currently active against it.
  3. 3MIRM's conflicting signal state resolves bearish — it currently carries 1 bullish and 2 bearish rules at once.
  4. 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

NAMS leads on balance
MetricMIRMNAMS
Revenue growth (YoY)5.4%4.2%
EPS growth (YoY)41.5%73.1%
Gross margin81.7%97.8%
Operating margin-25.3%-9%
Return on equity (TTM)75.2%-2.8%
Debt to equity-13.720

Performance

MIRM leads 5 of 6 windows
MetricMIRMNAMS
1 week (5 sessions)0.3%6.6%
1 month (20 sessions)17.3%1.6%
3 months (63 sessions)-5.8%-25.1%
6 months (126 sessions)-8%-43.2%
Year to date19%-42.6%
1 year (252 sessions)32.8%-47.4%

Technicals

MIRM has the stronger structure
MetricMIRMNAMS
RSI (14)59.947.3
ADX (14)26.116.7
Price vs 50-day5.9%-6.4%
Price vs 200-day-4.5%-30.9%
Volatility (1M, annualized)50.6%69.8%

Risk

Split
MetricMIRMNAMS
Beta1.071.43
Sharpe ratio0.79-0.91
Sortino ratio1.12-1.25
Max drawdown-38.4%-54.4%
Current drawdown-26.9%-51.4%
Annualized volatility48.6%53.8%
Value at risk (95%)-4.9%-5.2%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, MIRM or NAMS?

On the Algovestiq AIQ Score, MIRM is the stronger of the two as of Nov 15, 2026, scoring 53 against NAMS's 41. The edge comes from momentum and value. NAMS is not without a case — it holds the better quality profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is MIRM or NAMS the better buy right now?

MIRM carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Competitive — 3 of 6 covered evidence groups agree. A Competitive rating means the two are close enough that your objective, not the score, should decide.

Why does the AIQ Score favor MIRM over NAMS?

The composite weights Quality, Value, Momentum and Risk Resilience. MIRM leads Momentum by 32 points; MIRM leads Value by 15 points; NAMS leads Quality by 6 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, MIRM or NAMS?

Analyst price targets imply +66.9% upside for MIRM and +202.9% for NAMS, so the Street currently favors NAMS. That points the opposite way to the AIQ Score, which favors MIRM. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, MIRM or NAMS?

MIRM is the better-valued of the two on the peer-relative Value factor. MIRM on the peer-relative Value factor, by 15 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, MIRM or NAMS?

NAMS on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, MIRM or NAMS?

MIRM on the Momentum factor, by 32 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, MIRM or NAMS?

MIRM is the more resilient of the two, so the other name carries the higher downside risk. MIRM carries the lower 1-month annualized volatility. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is MIRM more profitable than NAMS?

The profitability evidence is mixed: gross margin 81.7% vs 97.8%; operating margin -25.3% vs -9%; ttm roe 75.2% vs -2.8%. MIRM leads on one measure and NAMS on two measures, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.

Is MIRM's lead over NAMS getting stronger or weaker?

MIRM lead: Stable — the AIQ differential has held near 12 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has not changed hands in that window.

What would change the MIRM vs NAMS verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: NAMS closes the Momentum gap — currently 32 points behind, the largest single contributor to MIRM's edge; NAMS's Death Cross Active resolves — a bearish trend rule currently active against it; MIRM's conflicting signal state resolves bearish — it currently carries 1 bullish and 2 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

What do the current signals say about MIRM and NAMS?

MIRM: 1 bullish / 2 bearish / 1 neutral, conflicted. NAMS: 1 bullish / 3 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on MIRM is Death Cross Active (bearish, long horizon). On NAMS it is Death Cross Active (bearish, long horizon).

Compare MIRM and NAMS with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.